September 27, 2011 09:08 ET

Latin American Pharmaceutical Market Is Worth $45 Billion

ROCKVILLE, MD--(Marketwire - Sep 27, 2011) - has announced the addition of the new market intelligence report "Healthcare & Pharmaceuticals in Latin America - A guide to the markets and regulations," to their collection of Pharmaceuticals market research. For more information, visit

Although Latin America offers substantial business opportunities for companies, it is a volatile region in economic terms. There is considerable risk involved in investing in the region and companies need to be fully aware of past economic crises and their causes before becoming involved. Latin America continues to be a region of promising opportunities for commercial pharmaceutical organizations. The region represents a growing consumer base for the drug industry as by 2020 the regional population may be as high as 687 million.

The Latin American pharmaceutical market is now worth $45 billion and multinational companies consider success in Brazil and Mexico as essential.

"Healthcare & Pharmaceuticals in Latin America - A guide to the markets and regulations" provides an excellent overview of the healthcare and pharmaceutical market in 19 Latin American countries.

This 40,000 word report, from URCH Publishing, provides an excellent review of the healthcare systems, politics, regulatory framework, major companies and key issues affecting the healthcare sector.

Some of the main issues concerning pharmaceutical companies operating in the region include:

  • Intellectual Property: Laws on intellectual property remain weak or are not enforced in a number of countries, leading legally ambiguous products on the market.
  • Generics: Regional governments are making serious attempts to encourage the use of generics (in the past the term bioequivalence was interpreted differing across countries) and Indian companies in particular have made headway into the major markets.
  • R&D: Companies are finding Latin America an attractive centre for R&D. There are currently an estimate 4,000 clinical trials being conducted. High enrolment rates, lower labor costs and improving regulation have estimated the growth in outsourcing.
  • Political Situation: Unsettling for multinational companies is the political shift to the left in some countries. However, a number of countries are working to introduce universal healthcare coverage which in turn could create excellent long term opportunities.

For more information, visit

About is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact